Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 143

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 143
---
 other public companies in which you hold equity interests.

In addition, the JOBS Act permits emerging growth companies to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period. As a result of this election, our timeline to comply with new or revised accounting standards will in many cases be delayed as compared to other public companies that are not eligible to take advantage of this election or have not made this election. Therefore, our financial statements may not be comparable to those of companies that comply with the public company effective dates for these accounting standards.

We are also a “smaller reporting company” as defined in the Exchange Act and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies. To the extent that we continue to qualify as a “smaller reporting company” as such term is defined in Rule 12b-2 under the Exchange Act, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an “emerging growth company” may continue to be available to us as a “smaller reporting company,” including exemption from compliance with the auditor attestation requirements pursuant to SOX and reduced disclosure about our executive compensation arrangements. We will continue to be a “smaller reporting company” until we have $250 million or more in public float (based on our Common Stock) measured as of the last business day of our most recently completed second fiscal quarter or in the event we have no public float (based on our Common Stock) or a public float (based on our Common Stock) that is less than $700 million, annual revenues of $100 million or more during the most recently completed fiscal year.

| 67 |

<div align='center'>MANAGEMENT</div>

The following is a list of our directors and executive officers as of April 10, 2025.

| Name            |     | Age |     | Position(s)                                    |
| Maria           
 Zannes, JD      |     |  69 |     | President,                                     
 CEO, and Director                              |
| James           
 Michael Edwards |     |  58 |     | Chief                                          
 Financial Officer                              |
| Xavier          
 Reveles         |     |  56 |     | Chief                                          
 Operating Officer                              |
| Timothy         
 P. Zannes, JD   |     |  72 |     | Executive                                      
 Vice President, Secretary, and General Counsel |
| Steven          
 Girgenti        |     |